Product Details

Purity

≥ 95% as determined by SDS-PAGE.
≥ 95% as determined by SEC-HPLC.

Endotoxin

Less than 1.0 EU/ug as determined by LAL method.

Activity

Measured by its binding ability in a functional ELISA. Immobilized Human PDGFRA at 2 μg/mL can bind Anti-PDGFRA recombinant antibody (CSB-RA017712MA1HU). The EC50 is 0.6497-0.8371 ng/mL.

Target Names

PDGFRA

Uniprot No.

P16234

Alternative Names

Platelet-derived growth factor receptor alpha; EC:2.7.10.1; PDGF-R-alpha; PDGFR-alpha; Alpha platelet-derived growth factor receptor; Alpha-type platelet-derived growth factor receptor; CD140 antigen-like family member A; CD140a antigen; Platelet-derived growth factor alpha receptor; Platelet-derived growth factor receptor 2 (PDGFR-2); CD140a; PDGFRA; PDGFR2, RHEPDGFRA

Species

Homo sapiens (Human)

Source

Mammalian cell

Expression Region

24-528aa

Target Protein Sequence

QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNGTFTVGPYICEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSELTVA

Mol. Weight

57.9 kDa

Protein Length

Partial

Tag Info

C-terminal 10xHis-tagged

Form

Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Buffer

Lyophilized from a 0.2 μm sterile filtered PBS, 6% Trehalose, pH 7.4

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.

Troubleshooting and FAQs

Protein FAQs

Storage Condition

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.

Shelf Life

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.

Lead Time

3-7 business days

Notes

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Datasheet & COA

Please contact us to get it.

Description

PDGFRA mediates critical signaling in vascular development and tissue repair, making its extracellular domain a key target for therapeutic antibody development and small-molecule inhibitor screening. This mammalian-expressed construct spanning residues 24–528 captures the complete ligand-binding region and demonstrates quantifiable antibody-binding activity with an EC50 of 0.65–0.84 ng/mL in functional ELISA, providing a validated basis for competitive inhibition assays, blocking antibody screening, and epitope mapping studies. The dual-method purity assessment—exceeding 95% by both SDS-PAGE and SEC-HPLC—combined with endotoxin levels below 1.0 EU/μg, satisfies the quality criteria typical for surface plasmon resonance and biolayer interferometry experiments where conformational integrity directly impacts affinity measurements. Researchers conducting ligand-receptor interaction studies or characterizing anti-PDGFRA therapeutic candidates will find this construct supports reproducible binding kinetics determination and serves as a reliable positive control in receptor-ligand interaction platforms.

Target Background

Function

Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor.

Gene References into Functions

Hepatic stellate cells release PDGFRalpha-enriched extracellular vesicles. Alcoholic liver disease patients show an increase in PDGFRalpha enrichment in their serum extracellular vesicles. PMID: 29360139
In addition to replicating a previously identified genome-wide significant locus for corneal astigmatism near the PDGFRA gene, gene-based analysis identified three novel candidate genes, CLDN7, ACP2, and TNFAIP8L3, that warrant further investigation to understand their role in the pathogenesis of corneal astigmatism. (Meta-analysis) PMID: 29422769
The present study showed that PDGFRA amplification could be effectively targeted by pazopanib. PMID: 30060824
KIT and PDGFRA mutations account for 85-90% of GISTs; subsequent genetic studies have led to the identification of mutation/epimutation of additional genes, including the succinate dehydrogenase (SDH) subunit A, B, C, and D genes. PMID: 29413424
we compared the efficacy of first-line therapy, doxorubicin (DOX), and TRAB in a platelet-derived growth factor receptor-alpha (PDGFRA)-amplified PLPS. METHODS: We used a fresh sample of PLPS tumor derived from a 68-year-old male patient diagnosed with a recurrent Pleomorphic liposarcoma PMID: 30126369
PDGFRA D842V mutant binds imatinib with lower affinity with respect to wild-type structure, showing higher stability during the interaction with other type I TKIs (like crenolanib). PMID: 29510530
Altered SK3 channel expression observed in PDGFRalpha(+) cells in UPJ obstruction suggests that the impairment of SK3 activity across the UPJ may perturb upper urinary tract peristalsis in this urological condition PMID: 28902181
None of the 16 analyzable tumors showed mutations in PDGFRA. Thus, PDGFRA mutations probably do not play an important role in the development of sporadic lipomas of the intestines PMID: 26990750
Whole transcriptome sequencing followed by pathway analysis indicated that STXBP4 is involved in functional gene networks that regulate cell growth, proliferation, cell death, and survival in cancer. Platelet-derived growth factor receptor alpha (PDGFRalpha) was a key downstream mediator of STXBP4 function. In line with this, shRNA mediated STXBP4 and PDGFRA knockdown suppressed tumor growth in soft-agar and xenograft ... PMID: 28087642
We report a unique case of an SDH-deficient GIST case with an activating PDGFRA mutation. Oncogenic mutations in GIST are generally mutually exclusive; however documented exceptions exist which may have diagnostic and therapeutic implications. PMID: 28768491
Case Report: concurrent development of myeloproliferative hypereosinophilic syndrome and lymphomatoid papulosis associated with FIP1L1-PDGFRA gene fusion. PMID: 28374041
Our results suggest that PDGFRalpha overexpression in HCC is a prognostic marker independent of adjacent non-tumor site liver fibrosis status. PMID: 28465473
PDGFRalpha/PDGFRbeta signaling balance determines progenitor commitment to beige (PDGFRalpha) or white (PDGFRbeta) adipogenesis. PMID: 29158445
overview of primary cilia-mediated regulation of receptor tyrosine kinase (RTK- PDGFRa and PDGFRb) and transforming growth factor beta (TGF-beta) signaling [review] PMID: 27638178
PDGFRA mutation, but not amplification is associated with older age in pediatric high-grade glioma. PMID: 27582545
Study demonstrates for the first time that PDGFR-alpha strongly inhibits endothelial and melanoma cells proliferation in a CXCL10/IP-10 dependent way, via miR-503 down-regulation. PMID: 27764787
PDGFRalpha activation is an essential component that drives aggressiveness in papillary thyroid carcinoma cells. The signaling pathways are complex, involving not only the MAPK/Erk but also the PI3K/Akt and STAT3 pathways. PMID: 27845909
Here, the authors provide a 19 A reconstruction for the cytomegalovirus gHgLgO trimer and show that it binds with high affinity through the gO subunit to PDGFRalpha, which is expressed on fibroblasts but not on epithelial cells. PMID: 27573107
Perivascular PDGFR-alpha and -beta were identified as independent markers predicting survival in metastatic colorectal cancer (mCRC). PMID: 27248825
Data suggest that the platelet derived growth factor receptor alpha (PDGFRalpha)/Stat3 transcription factor/Rb1 protein regulatory axis might represent a potential therapeutic target for glioblastoma (GBM) treatment. PMID: 27344175
Point mutations in the PDGFRa gene, which leads to amino acid residue changes activating the kinase of the receptor, occur in about 5% of Gastrointestinal Stroma Tumors. An activating deletion mutation of the PDGFRA gene has been described in a human Glioblastoma. PMID: 28940884
FIP1L1/ PDGFRA associated chronic eosinophilic leukemia has an excellent long-term prognosis following imatinib therapy. PMID: 27120808
Olaratumab had an acceptable adverse event profile in patients with gastrointestinal stromal tumor (GIST). While there was no apparent effect on PFS in patients without PDGFRa mutations, patients with PDGFRalpha-mutant GIST (all with D842V mutations) treated with olaratumab had longer disease control compared with historical data for this genotype PMID: 28426120
For hot spots in KIT and PDGFRA genes, 23 out of 146 KIT/PDGFRA wild-type cases carried mutations according to next-generation sequencing (NGS). PMID: 26848617
In vitro activation of PDGFR-alpha leads to translational activation of LAMB1, which in turn induces an invasive and metastatic phenotype of hepatocellular carcinoma cells exhibiting K19 expression. PMID: 28783171
PDGFRalpha levels are regulated by SMARCB1 expression, and assessment of clinical specimens documents the expression of both PDGFRalpha and FGFR1 in rhabdoid tumor patients. PMID: 27783942
The downregulation of platelet-derived growth factor receptor-alpha expression may play a causative role in imatinib-induced thrombocytopenia, a common side effect, in the subset of chronic myeloid leukemia patients with platelet-derived growth factor receptor-alpha +68 GA ins/del, +68 GA del/del, and -909C/A genotypes. PMID: 29019285
These findings support a distinct contribution of PDGFRalpha signaling to hepatic stellate cell proliferation and migration. PMID: 28734947
Data indicate that co-inhibition of FGFR1 and HER2 or PDGFRalpha led to enhanced drug responses. PMID: 26549034
High PDGFRA expression is associated with pathogenesis of malignant peripheral nerve sheath tumor. PMID: 27477693
The interaction between CSR1 and SF3A3 led to migration of SF3A3 from nucleus to cytoplasm. The cytoplasmic redistribution of SF3A3 significantly reduced the splicing efficiency of epidermal growth factor receptor and platelet-derived growth factor receptor. PMID: 27148859
PDGFRa amplification in multiple skin lesions of undifferentiated pleomorphic sarcoma PMID: 28105789
in addition to representing a white adipose tisseu (WAT) adipogenic niche, different PDGFRalpha(+) cell subsets modulate obesity-induced WAT fibrogenesis and are associated with loss of metabolic fitness. PMID: 28215843
PDGFRA mutations were associated with gastrointestinal stromal tumors. PMID: 28098915
The PDGFRA kinase domain structure we report in this study has potential to facilitate development of new agents which can inhibit this kinase, including both its activating and drug-resistant mutations. PMID: 27349873
BRAF mutations are rare events in KIT/PDGFRA wild-type gastrointestinal stromal tumors. PMID: 28159677
There are two platelet-derived growth factor receptor (PDGFR) genes (PDGFRA and PDGFRB), and they reside on chromosome 4 and 5. PMID: 28267575
Data did not detect any significant association with SNPs of APRIL, SPATA8, PDGFRA, and POLB with Systemic Lupus Erythematosus in Chinese Han Population. PMID: 27569236
Synchronous T lymphoblastic lymphoma and myeloid neoplasm with PDGFRA rearrangement. PMID: 28013529
Stromal expression of PDGFRA increased with increasing histologic grade of breast phyllodes tumor. PDGFR stromal positivity was associated with shorter overall survival. PMID: 27881889
genome analysis of wild-type gastrointestinal stromal tumors for mutations should include the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors PMID: 27864688
We demonstrate in cell lines, SCID xenografts and human tumor specimens that PDGFRalpha promotes dedifferentiation in PTC by decreasing TTF1 expression in the nucleus, which decreases iodide transport and thyroglobulin production in thyroid follicular cells. PMID: 27682510
Increased PDGFRA expression is associated with thyroid papillary carcinoma. PMID: 26715280
PDGFRA was a direct target of miR-34a in human pulmonary artery smooth muscle cells. PMID: 27302634
Lack of PDGFRalpha(+)-cells in both the aganglionic and ganglionic Hirschsprung's disease bowel may contribute to the motility dysfunction. PMID: 27022215
Ku80 and PDGFR-alpha might be effective predictive indicators for the prognosis of nasal type NK/T cell lymphoma PMID: 26778387
miR-140-5p acts as a tumor suppressor during ovarian carcinogenesis, inhibiting ovarian cancer growth partially by repressing PDGFRA expression. PMID: 26297547
This study identified KIT and PDGFRA mutations in 21 out of 25 gastrointestinal stromal tumor samples from 2 referential national hospitals in Peru. PMID: 25659388
we retrospectively examined correlations between clinical outcomes and KIT/PDGFRA mutational status in a subset of imatinib-resistant or -intolerant patients with stromal tumor participating in a worldwide, open-label treatment-use study PMID: 26772734
Data characterized metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) genetic susceptibility genes beyond kit proto-oncogene protein (KIT)/PDGF alpha receptor (PDGFRalpha) genotype. PMID: 26544626

Hide All

Involvement in disease

Gastrointestinal stromal tumor (GIST)

Subcellular Location

Cell membrane; Single-pass type I membrane protein. Cell projection, cilium. Golgi apparatus.

Protein Families

Protein kinase superfamily, Tyr protein kinase family, CSF-1/PDGF receptor subfamily

Tissue Specificity

Detected in platelets (at protein level). Widely expressed. Detected in brain, fibroblasts, smooth muscle, heart, and embryo. Expressed in primary and metastatic colon tumors and in normal colon tissue.

Database Links

HGNC: 8803

OMIM: 173490

KEGG: hsa:5156

STRING: 9606.ENSP00000257290

UniGene: Hs.74615

Code	CSB-MP017712HU1
Abbreviation	Recombinant Human PDGFRA protein, partial (Active)
MSDS	MSDS Datasheet
Size	$118
	Order now
Image	(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel. Activity Measured by its binding ability in a functional ELISA. Immobilized Human PDGFRA at 2 μg/ml can bind Anti-PDGFRA recombinant antibody (CSB-RA017712MA1HU). The EC₅₀ is 0.6497-0.8371 ng/mL. Biological Activity Assay The purity of PDGFRA was greater than 95% as determined by SEC-HPLC
Have Questions?	Leave a Message or Start an on-line Chat

Recombinant Human Platelet-derived growth factor receptor alpha (PDGFRA), partial (Active)

Product Details

Related Products

Customer Reviews and Q&A

Target Background

×CloseMessage